Vivaldi Biosciences
Home About Vivaldi
News Publications Contact us
DeltaFlu DelNS1 H5N1 Delta-19
Home Pipeline DeltaFlu DelNS1 H5N1 Delta-19 About Vivaldi
Vivaldi Biosciences
NewsPublicationsContact us
Vivaldi Biosciences Board Appoints William Wick as Chief Executive Officer and John Costantino as Chairman Fort Collins, CO – May 22, 2017 - Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing genetically attenu
OldYoy Design AgencyMay 17, 2019
Vivaldi Biosciences Appoints Manfred Reiter, PhD as Senior Vice President, Manufacturing Fort Collins, CO – April 28, 2017- Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing genetically attenuated live influen
OldYoy Design AgencyMay 17, 2019
Newer
 

News

News
Vivaldi Biosciences Granted U.S. Patent for Nasal Spray Combination Vaccine for Influenza and COVID-19
September 1, 2026
Vivaldi Biosciences Granted U.S. Patent for Nasal Spray Combination Vaccine for Influenza and COVID-19
September 1, 2026
Read more →
September 1, 2026
Innovations for Clinical Development of a Broadly Protective Nasal Spray Flu Vaccine to be Presented by Vivaldi Biosciences at ISRV Options XIII Conference
August 25, 2026
Innovations for Clinical Development of a Broadly Protective Nasal Spray Flu Vaccine to be Presented by Vivaldi Biosciences at ISRV Options XIII Conference
August 25, 2026
Read more →
August 25, 2026
Vivaldi Biosciences Granted U.S. Patent for Universal Influenza Vaccine
November 19, 2025
Vivaldi Biosciences Granted U.S. Patent for Universal Influenza Vaccine
November 19, 2025
Read more →
November 19, 2025
Vivaldi Biosciences to Present DeltaFLU Universal Influenza Vaccine Study Results at ISRV Meeting
October 7, 2025
Vivaldi Biosciences to Present DeltaFLU Universal Influenza Vaccine Study Results at ISRV Meeting
October 7, 2025
Read more →
October 7, 2025
Vivaldi Biosciences Announces Issuance of U.S. Patent Enabling Rapid Manufacture of its Universal Influenza Vaccine
July 21, 2025
Vivaldi Biosciences Announces Issuance of U.S. Patent Enabling Rapid Manufacture of its Universal Influenza Vaccine
July 21, 2025
Read more →
July 21, 2025
 

Home DeltaFlu Delta-19 The need About Vivaldi News Publications Contact US

 
Logo-03.png
 

© Vivaldi Biosciences Inc. All Rights Reserved 2026

 

Vivaldi Biosciences is not interviewing to fill positions and is not hiring at this time. Beware of hiring scams that arrange online interviews, promptly offer a job, and ask for personal information such as your driver’s license number, social security number, or bank account information. If you believe you are a victim of a hiring scam you may notify the Federal Trade Commission: https://reportfraud.ftc.gov/ - /

Disclaimer: Delta NS1 vaccines are currently under clinical investigation and are not approved for human use in any country or region.